The Pharma Data

JUNE 17, 2022

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe.

Biosimilars 52

Biosimilars Pharmacokinetics FDA Approval Packaging 52

Drug Discovery World

AUGUST 22, 2023

This will continue to be the case going forward, but the nature of the off-patent landscape will evolve in line with ongoing changes in the segment’s ‘pipeline’: the originator products of today, which will become the generic and biosimilar medicines of tomorrow. There is significant need for more cost-effective generic versions.

Production 130

Production Pharma Companies Clinical Trials FDA 130

The Pharma Data

JULY 27, 2021

“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. ” In June 2021, AbbVie Inc.

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

FEBRUARY 8, 2021

Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis. DISCLOSURE NOTICE : The information contained in this release is as of February 5, 2021. hypoxia, cough, dyspnea).

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . About Aducanumab. The safety and tolerability of aducanumab was the primary aim of the study. About Alzheimer’s Disease.

Disease 40

Disease FDA Clinical Trials Licensing 40

Agency IQ

FEBRUARY 15, 2024

In other cases, the FDA is under no obligation to release a document at any time, but is instead developing the document on its own accord. We have tried to sort guidance documents by topic area. Priority A List.

FDA 40

FDA Science Biosimilars Production 40

The Premier Consulting Blog

APRIL 25, 2023

This act amends the Federal Food, Drug, and Cosmetic Act (FFDCA), which applies to new drugs, and the Public Health Service Act, which applies to biosimilars. Synthroid® oral tablets) were marketed as unapproved drugs for the treatment of hypothyroidism in the US. This strategy can reduce the overall study requirements for approval. [1]

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52